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ABSTRACT
Cryptococcal meningitis is the most common cause of opportunistic meningitis in HIV-
infected patients in Brazil and causes unacceptable high mortality rates. In this study, HIV-
infected patients with a first episode of culture-proven cryptococcal meningitis in cerebrospinal 
fluid (CSF) were prospectively included in order to evaluate sensitivity of cryptococcal antigen 
(CrAg) lateral flow assay (LFA) in serum, CSF, whole blood (fingerstick), and fresh urine. 
In addition, HIV-infected patients with other neurological confirmed diseases were included 
in order to evaluate the specificity of CrAg LFA in serum. Twenty patients with cryptococcal 
meningitis were included and in 19 of them, CrAg LFA in CSF, serum, and whole blood were 
positive (95% sensitivity). In 18 patients, India ink test was positive in CSF (90% sensitivity), 
and in 16 cases, CrAg LFA was positive in urine (80% sensitivity). Thirty-six HIV-infected 
patients with other neurological diseases had negative results of CrAg LFA in serum (100% 
specificity). In conclusion, CrAg LFA in serum, CSF, and whole blood showed high sensitivity 
and specificity. Whole blood CrAg LFA seems to be a good and reliable strategy to improve 
AIDS-related cryptococcal meningitis diagnosis in Brazil. 
KEYWORDS: Cryptococcal meningitis. Cryptococcosis. Diagnosis. Human 
immunodeficiency virus. Acquired immunodeficiency syndrome.
INTRODUCTION
The number of cases of cryptococcal meningitis diminished in the highly active 
antiretroviral therapy (HAART) era in Brazil. However, Cryptococcus neoformans 
continues to be the most common cause of opportunistic meningitis in our setting 
and causes high lethality rates1. The World Health Organization (WHO) recommends 
the use of cryptococcal antigen (CrAg) assays by latex agglutination or lateral flow 
assay (LFA) as the preferred diagnostic approaches for cryptococcal meningitis 
diagnosis in resource-limited settings2. CrAg LFA (Immuno-Mycologics, Norman, 
OK, USA) is an immunochromatographic assay that can be used in settings with 
minimal or no infrastructure. CrAg LFA is the only commercially available CrAg 
assay that complies with WHO ASSURED criteria (Affordable, Sensitive, Specific, 
User friendly, Rapid/robust, Equipment-free, and Delivered)3 for diagnostic tests. 
In addition, CrAg LFA has better analytical sensitivity than other commercial 
assays for both C. neoformans and C. gatti4. The CrAg LFA has been approved 
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by the U.S. Food and Drug Administration (FDA) for use 
in serum and cerebrospinal fluid (CSF) specimens, and 
similar use has recently been released in Brazil. However, 
unvalidated specimen types of whole blood or urine 
constitute potentially ideal samples for point-of-care testing 
of individual patients. The diagnostic performance in urine 
or whole blood is less clear.  
In this validation  study, we evaluated the performance 
of CrAg LFA in HIV-infected patients with cryptococcal 
meningitis.
PATIENTS AND METHODS
Group 1: Cryptococcal meningitis
Twenty HIV-infected patients in their first episode of 
cryptococcal meningitis confirmed by CSF fungal culture 
were included in order to evaluate the sensitivity of CrAg 
LFA in serum, CSF, whole blood (fingerstick) and fresh 
urine samples. For CSF and serum samples, manufacturer‘s 
instructions were followed, and for whole blood and urine, 
already established protocols5,6. In addition, cerebrospinal 
India Ink and fungal blood culture were obtained in all 
cases, at admission. All patients received amphotericin B 
deoxycholate (0.7 to 1.0 mg/kg/day, intravenously) and 
fluconazol (800 mg/day, orally in two divided doses) or 
flucytosine (100 mg/kg/day, orally, in four divided doses) 
were associated for at least two weeks, in 18 and 2 cases, 
respectively. Subsequently, fluconazole (400-800 mg per 
day, orally) was prescribed for at least eight weeks. Nine 
(45%) patients had intracranial hypertension at diagnosis 
with CSF opening pressure of 25 cmH2O, requiring serial 
lumbar punctures. In four (20%) cases, neurosurgery was 
performed and a lumbar peritoneal shunt was placed in 
order to control intracranial pressure.
Group 2: HIV controls
Thirty-six HIV-infected patients with other confirmed 
neurological diseases were included in order to evaluate the 
specificity of CrAg LFA in serum. Sensitivity was defined 
as the probability that a test result will be positive when the 
disease is present (true positive rate). Specificity was defined 
as the probability that a test result will be negative when 
the disease is not present (true negative rate). In addition, a 
95% confidence interval (95% CI) was calculated. 
Participants were prospectively recruited over a period 
of one year at the Emilio Ribas Institute of Infectious 
Diseases, São Paulo, Brazil. The study was conceived in 
the Cryptococcosis Brazilian Network, which provided the 
CrAg LFA kits, and was approved by the Research Ethics 
Committee of the hospital (Research Protocol Nº 46/2014). 
All study participants provided written informed consent. 
Analysis was primarily descriptive reporting the diagnostic 
performance. 
RESULTS
Group 1: Cryptococccal meningitis
The mean age (±SD) was 39.9 (± 6.2) years old, and 
12 subjects (60%) were men. Cryptococcal meningitis 
was the initial AIDS-definition disease in 11 (55%) cases. 
Fifteen (75%) patients were HAART experienced; however, 
none of them was under medications at admission. The 
CD4 cell count median was 42 (Range: 1 – 176) cells/
µL. Among the 20 patients, the first lumbar puncture 
demonstrated culture-proven diagnosis of cryptococcal 
meningitis in 18 cases. In the other 2 patients, culture-
proven diagnosis was obtained from the second lumbar 
puncture. In all 20 cases, C. neoformans was identified. 
Among the 20 patients, 19 had positive CrAg LFA in CSF, 
serum, and whole blood samples (95% sensitivity; 95% CI: 
75.13% to 99.87%). In 18 patients (90%), CSF India ink 
was positive at admission. In one case, the single positive 
test was CSF fungal culture. This case was one of the two 
with proven diagnosis by the culture in the second lumbar 
puncture, performed one day after the first one. The false 
negative result of CrAg LFA was perfomed with the sample 
of the second lumbar puncture. Sixteen (80%) patients 
had positive CrAg LFA in urine; in six patients (32%), 
C. neoformans growing was observed in blood culture. Two 
(10%) patients died during hospitalization, and 18 (90%) 
were discharged home. 
Group 2: HIV controls
In all thirty-six controls, serum CrAg LFA was negative 
(100% specificity; 95% CI: 90.3% to 100.0%). Among 
them, 18 controls with tuberculous meningitis; 9 controls 
with neurosyphilis; 5 controls with progressive multifocal 
leukoencephalopathy; 3 controls with cytomegalic 
encephalitis; and 1 control with cerebral toxoplasmosis. 
DISCUSSION
Our prospective study reinforces the diagnostic value 
of serum and CSF CrAg LFA testing in patients with 
cryptococcal meningitis. A systematic review showed a 
pooled sensitivity of serum CrAg LFA of 97.6% (95% CI, 
95.6% to 98.9%) and CSF CrAg LFA of 98.9% (95% 
CI, 97.9% to 99.5%). In addition, this review pointed 
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out a pooled specificity of serum CrAg LFA of 98.1% 
(95% CI, 97.4% to 98.6%) and CSF CrAg LFA of 98.9% 
(95% CI, 98% to 99.5%)7. More interestingly, we found 
100% agreement between whole blood and serum CrAg 
LFA results, as previously reported5. Thus, although it is 
not a FDA approved specimen, whole blood or plasma 
are a reliable and practical fluid for CrAg LFA tool for 
detection of CrAg as a point-of-care test. Our results have 
also emphasized that urine has limitations given its pooled 
sensitivity of 85.0% (95% CI, 78.7% to 90.1%)7. 
CrAg LFA implementation constitutes a great opportunity 
to optimize diagnosis time and resources in settings where 
cryptococcal meningitis is a main cause of opportunistic 
meningitis in HIV-infected persons. Nowadays, in several 
hospital referral centers in Brazil, when a first CSF is 
collected from an HIV-infected patient with clinical 
suspicion of meningitis or meningoencephalitis, several 
tests are requested, including most of the following tests: 
Gram’s stain; acid-fast bacillus (AFB) smear; bacterial, 
fungal and mycobacterial cultures; pan-Herpes PCR; 
nucleic acid amplification tests for tuberculosis and a 
CrAg latex agglutination assay. On the other hand, in most 
centers with lesser resources, it is relevant to strategically 
identify which tests are the most relevant to diagnosis. 
As recently proposed, development of algorithms using a 
fingerstick CrAg LFA as an initial test seems to be more 
rational for investigating meningitis or meningoencephalitis 
in HIV-infected patients5. 
Despite the advantages of CrAg LFA versus other 
tests, there are several barriers to incorporate this tool into 
routine testing. For example, the price of each test in São 
Paulo is approximately US$ 9.5 (Interlab - Distribuidora de 
Produtos Científicos Ltda, in March the 6th, 2017), similar to 
the price of the most popular local CrAg latex agglutination 
assay. This price is two-fold higher than purchase price in 
the United States of America. 
In conclusion, CrAg LFA  in serum, CSF and whole 
blood showed high sensitivity and specificity. Whole 
blood CrAg LFA seems to be a simple strategy to improve 
diagnosis of AIDS-related cryptococcal meningitis in 
Brazil. Despite current barriers, implementation of this 
tool could reduce costs by streamlining diagnostic testing. 
REFERENCES
 1. Vidal JE, Penalva de Oliveira AC, Dauar RF, Boulware DR. 
Strategies to reduce mortality and morbidity due to AIDS-
related cryptococcal meningitis in Latin America. Braz J Infect 
Dis. 2013;17:353-62.
 2. World Health Organization. Rapid advice: diagnosis, prevention 
and management of cryptococcal disease in HIV-infected 
adults, adolescents and children. Geneva: WHO; 2011.
 3. Kozel TR, Bauman SK. CrAg lateral flow assay for cryptococcosis. 
Expert Opin Med Diagn. 2012;6:245-51. 
 4. Vidal JE, Boulware DR. Lateral flow assay for cryptococcal 
antigen: an important advance to improve the continuum of 
HIV care and reduce cryptococcal meningitis-related mortality. 
Rev Inst Med Trop Sao Paulo. 2015;57 Suppl 19:38-45.
 5. Williams DA, Kiiza T, Kwizera R, Kiggundu R, Velamakanni 
S, Meya DB, et al. Evaluation of fingerstick cryptococcal 
antigen lateral flow assay in HIV-infected persons: a diagnostic 
accuracy study. Clin Infect Dis. 2015;61:464-7. 
 6. Magambo KA, Kalluvya SE, Kapoor SW, Seni J, Chofle AA, 
Fitzgerald DW, et al. Utility of urine and serum lateral 
flow assays to determine the prevalence and predictors 
of cryptococcal antigenemia in HIV-positive outpatients 
beginning antiretroviral therapy in Mwanza, Tanzania. J Int 
AIDS Soc. 2014;17:19040. 
 7. Huang HR, Fan LC, Rajbanshi B, Xu JF. Evaluation of a 
new cryptococcal antigen lateral flow immunoassay in 
serum, cerebrospinal fluid and urine for the diagnosis of 
cryptococcosis: a meta-analysis and systematic review. PLoS 
One. 2015;10:e127117.
